PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
24433865-4	2014	A non-clinically significant, elacytarabine exposure-dependent increase in cholesterol was caused by a cholesterol rich lipoprotein depleted of apolipoprotein B formed by infused phospholipids complexing cholesterol.	5'-oleoyl cytarabine	30-43	apolipoprotein B	Homo sapiens	144-160
25469211-3	2014	Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP.	5'-oleoyl cytarabine	0-13	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	204-242
25469211-3	2014	Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP.	5'-oleoyl cytarabine	0-13	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	244-249
25469211-3	2014	Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP.	5'-oleoyl cytarabine	0-13	cytidine deaminase	Homo sapiens	326-344
25469211-3	2014	Elacytarabine, a lipophilic 5"-elaidic acid ester or nucleoside analogue of cytosine arabinoside, was created with the intent of overcoming resistance mechanisms including reduced expression of the human equilibrative nucleoside transporter 1 (hENT1) required for cytarabine entry into cells, as well as increased activity of cytidine deaminase (CDA) which breaks down the active metabolite of cytarabine, ara-CTP.	5'-oleoyl cytarabine	0-13	cytidine deaminase	Homo sapiens	346-349
25469211-7	2014	Use of hENT1 expression as a predictive marker for cytarabine or elacytarabine response has been studied with no conclusive validation to date.	5'-oleoyl cytarabine	65-78	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	7-12
24255981-4	2014	The hENT1 expression level was analyzed prior to first induction and/or prior to treatment with elacytarabine.	5'-oleoyl cytarabine	96-109	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	4-9
24023287-1	2013	AIM: The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5"-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts.	5'-oleoyl cytarabine	91-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	322-362
24023287-1	2013	AIM: The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5"-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts.	5'-oleoyl cytarabine	91-104	vascular endothelial growth factor A	Homo sapiens	234-268
24023287-1	2013	AIM: The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5"-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts.	5'-oleoyl cytarabine	91-104	vascular endothelial growth factor A	Homo sapiens	270-274
24023287-1	2013	AIM: The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5"-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts.	5'-oleoyl cytarabine	91-104	epidermal growth factor receptor	Homo sapiens	277-309
24023287-1	2013	AIM: The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5"-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts.	5'-oleoyl cytarabine	91-104	epidermal growth factor receptor	Homo sapiens	311-315
24023287-1	2013	AIM: The objective of the present study was to determine the in vivo antitumor activity of elacytarabine, the 5"-elaidic acid ester of arabinofuranosyl cytidine, alone and in combination with bevacizumab, cetuximab and trastuzumab in Vascular endothelial growth factor (VEGF), Epidermal growth factor receptor (EGFR)- and Human epidermal growth factor receptor 2 (HER2)-expressing non-small cell lung cancer xenografts.	5'-oleoyl cytarabine	91-104	erb-b2 receptor tyrosine kinase 2	Homo sapiens	364-368
23902239-2	2013	Elacytarabine was rationally designed to circumvent cytarabine resistance related to decreased cellular uptake, due to the ability of the lipophilic drug moiety to enter the cell without the requirement of specialized nuclear transport proteins, including the hENT1.	5'-oleoyl cytarabine	0-13	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	260-265
22702906-1	2012	Elacytarabine is a novel cytotoxic nucleoside analogue, independent of nucleoside transporters (e.g. human Equilibrative Nucleoside Transporter 1 [hENT1]) for cell uptake, and mechanisms of action similar to those of cytarabine.	5'-oleoyl cytarabine	0-13	solute carrier family 29 member 1 (Augustine blood group)	Homo sapiens	147-152